Postmenopausal Osteoporosis and Osteopenia Management with a Combination of Once-Monthly Oral Ibandronate and Cholecalciferol—A Systematic Review  

作　　者：Mauro Geller Mendel Suchmacher Marcio Cohen Spyros G. E. Mezitis Flavia Wajnsztajn-Theil Karin G. Cunha Rafael Nigri Mauro Geller;Mendel Suchmacher;Marcio Cohen;Spyros G. E. Mezitis;Flavia Wajnsztajn-Theil;Karin G. Cunha;Rafael Nigri(Teresópolis Medical Faculty, Rio de Janeiro Federal University, Rua Bruno Lobo, Brazil;Carlos Chagas Post-graduation Institute, Rio de Janeiro, Brazil;Orthopedic Surgery and Trauma National Institute, Rio de Janeiro, Brazil;Weill Medical College of Cornell University, New York, USA;Lenox Hill Hospital Northwell Health, New York, USA;Fluminense Federal University, Antonio Pedro Hospital, Rio de Janeiro, Brazil;New Jersey Medical School, New York, USA)

机构地区：[1]Teresópolis Medical Faculty, Rio de Janeiro Federal University, Rua Bruno Lobo, Brazil [2]Carlos Chagas Post-graduation Institute, Rio de Janeiro, Brazil [3]Orthopedic Surgery and Trauma National Institute, Rio de Janeiro, Brazil [4]Weill Medical College of Cornell University, New York, USA [5]Lenox Hill Hospital Northwell Health, New York, USA [6]Fluminense Federal University, Antonio Pedro Hospital, Rio de Janeiro, Brazil [7]New Jersey Medical School, New York, USA

出　　处：《International Journal of Clinical Medicine》2023年第1期34-57,共24页临床医学国际期刊（英文）

摘　　要：Postmenopausal osteoporosis and osteopenia are chronic and uncurable conditions that invariably lead to an increased risk of vertebral, hip, and femoral neck fracture if left untreated. Clinical guidelines establish, in general, pharmacological combinations allied to lifestyle changes as the mainstay of their management, and also increasing bone marrow density, lowering fracture risk, and improving quality of life are their main therapeutic goals. The objective of this systematic review was to analyze the available data in the scientific medical literature regarding the role of the ibandronate and cholecalciferol combination in postmenopausal osteoporosis and osteopenia management. Based on our results, we concluded that the above combination is safe and feasible for the clinical control of both conditions.Postmenopausal osteoporosis and osteopenia are chronic and uncurable conditions that invariably lead to an increased risk of vertebral, hip, and femoral neck fracture if left untreated. Clinical guidelines establish, in general, pharmacological combinations allied to lifestyle changes as the mainstay of their management, and also increasing bone marrow density, lowering fracture risk, and improving quality of life are their main therapeutic goals. The objective of this systematic review was to analyze the available data in the scientific medical literature regarding the role of the ibandronate and cholecalciferol combination in postmenopausal osteoporosis and osteopenia management. Based on our results, we concluded that the above combination is safe and feasible for the clinical control of both conditions.

关 键 词：IBANDRONATE CHOLECALCIFEROL Postmenopausal Osteoporosis Postmenopausal Osteopenia Systematic Review 

分 类 号：R58[医药卫生—内分泌]